What is Candel Therapeutics, Inc. (CADL) stock price today?

Candel Therapeutics, Inc. (CADL) is currently trading at $9.94, up 2.9% today.

What is CADL P/E ratio?

Candel Therapeutics, Inc.'s P/E ratio is -7.22. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CADL return on equity (ROE)?

Candel Therapeutics, Inc.'s return on equity (ROE) is -89.38%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Candel Therapeutics, Inc.'s market cap?

Candel Therapeutics, Inc. has a market capitalization of $728.31M.

NASDAQ · Biotechnology

Candel Therapeutics, Inc. (CADL) Stock

$9.94 +2.90% NASDAQ: CADL Healthcare

Valuation

Metric	Value
Price	$9.94
Market Cap	$728.31M
P/E Ratio	-7.22
P/B Ratio	5.98
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$14.00
52-Week Low	$4.35
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-89.38%
ROA	-42.53%
ROCE	-36.83%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.39
Current Ratio	13.33

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-26.0M	$-35.0M	$-38.0M	$-33.0M	$-48.0M
Net Profit	$-36.0M	$-19.0M	$-38.0M	$-55.0M	$-38.0M
EPS	$-1.91	$-0.10	$-1.31	$-1.74	$-0.72
Op Margin	-20580.8%	-27739.2%	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$89.0M	$79.0M	$41.0M	$107.0M	$125.0M
Total Liabilities	$25.0M	$31.0M	$28.0M	$41.0M	$73.0M
Cash	$83.0M	$70.0M	$35.0M	$103.0M	$120.0M
Borrowings	$1.0M	$23.0M	$23.0M	$13.0M	$2.0M

Latest News

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 8, 2026 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 1, 2026 CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’ Stocktwits · Jun 30, 2026 Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors GlobeNewswire · Jun 30, 2026 Candel Therapeutics Designates Mark Sims as CCO Exec Edge · Jun 25, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-22.0M	$-31.0M	$-34.0M	$-27.0M	$-38.0M
Investing Cash Flow	$-4.0M	$-3.0M	$-1.0M	$0	$-1.0M
Financing Cash Flow	$0	$0	$0	$2.0M	$0
Net Cash Flow	$48.0M	$-13.0M	$-35.0M	$67.0M	$17.0M
Free Cash Flow	$-24.0M	$-33.0M	$-35.0M	$-27.0M	$-39.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.09
EV / EBITDA	-7.16
FCF Yield	-7.68%
Quick Ratio	16.09
Interest Coverage	-15.26
Return 1Y	41.67%
Return 3Y	772.57%
Return 5Y	—

Ownership

Insiders Held15.53%

Institutions Held60.02%

Institutions Float Held71.05%

Institutional Holder	Shares	Report Date
FMR, LLC	10,987,017	2026-03-31
RTW Investments LP	6,422,018	2026-03-31
Acorn Capital Advisors, LLC	3,497,948	2026-03-31
Blackrock Inc.	3,109,042	2026-03-31
Saturn V Capital Management LP	2,896,588	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
GNLXGenelux Corporation	$2.56	+2.40%	-2.88	$114.79M	0.00%
IMMXImmix Biopharma, Inc.	$9.46	+1.83%	-11.00	$514.64M	0.00%
INABIN8bio, Inc.	$1.34	-2.90%	-0.75	$12.85M	0.00%
IOVAIovance Biotherapeutics, Inc.	$14.62	+9.84%	-20.16	$6.53B	0.00%
IPSCCentury Therapeutics, Inc.	$1.47	+0.68%	-1.43	$266.18M	0.00%

About Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is led by CEO Paul-Peter Tak, employs 38 people, headquartered in US, publicly traded since 2021.

Candel Therapeutics, Inc. (CADL) stock trades at $9.94 with a market capitalization of $728.31M. The stock is valued at a price-to-earnings (P/E) ratio of -7.22, price-to-book of 5.98, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.35 and $14.00, and currently trades 29.0% below its 52-week high.

On profitability, Candel Therapeutics, Inc. generates a return on equity (ROE) of -89.38%, return on capital employed of -36.83%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides